Phase 4 Melanoma Trial, Recruiting NCT07445022 Sponsor: Fudan University Condition: Melanoma
Back to Melanoma

Phase 4 Melanoma Trial, Recruiting

NCT07445022
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People with melanoma (a type of skin cancer) that has spread to nearby tissue or other parts of the body, confirmed through a laboratory test of a tissue or cell sample
  • People whose cancer test results show a specific genetic change called an NRAS mutation
  • People whose melanoma has not responded to, or has stopped responding to, a previous type of immunotherapy treatment (known as anti-PD-1 or PD-L1 therapy)
  • People who are able to swallow and digest oral (tablet or capsule) medications
  • People who are willing to take part, able to sign a consent form, and able to follow the study's requirements throughout the trial

Who may not be able to join:

  • People who are currently taking part in another clinical trial involving a drug or medicine
  • People who are pregnant or currently breastfeeding
  • People whose overall health situation has been reviewed by a medical team and considered unsuitable for this type of targeted treatment (confirm with trial site)
  • People who the trial investigator considers unsuitable for other reasons, such as personal, family, or social circumstances that could affect their safety or the reliability of the trial data

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 86-021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
28 January 2026
Est. completion
30 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov